Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDK6 siRNA
- Development stage
- Preclinical
- Lead developer
- Chung Shan Medical University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CDK6 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Cyclin-dependent kinase 6 (CDK6) through the RNA interference (RNAi) pathway. CDK6 is a critical regulator of the G1 to S phase transition in the cell cycle and has been implicated in the maintenance of cancer stem cell (CSC) populations. In preclinical models of endometrial cancer, the use of CDK6 siRNA has been shown to significantly reduce cell proliferation, migration, and tumorsphere formation, while also downregulating stemness-related transcription factors such as OCT4, NANOG, and c-MYC. This modality is primarily utilized as a research tool to investigate the therapeutic potential of CDK6 inhibition in various malignancies.
- Other names
- siCDK6siCDK-6siCDK 6CDK6 small interfering RNACDK-6 small interfering RNACDK 6 small interfering RNA
02
Targets
CDK6 (Cyclin-dependent kinase 6)
Beyond the preview
Go deeper on CDK6 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDK6 siRNA.